Global health groups push to make cheap generic versions of an HIV prevention drug sold by Gilead

Taking stock of the drug industry, from the lab to the medicine chest

September 24, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Nardus Engelbrecht/AP STAT+ | Global health groups push to make cheap generic versions of an HIV prevention drug sold by Gilead The Gilead Sciences drug, called lenacapavir, has been hailed as a tool that could bring the 45-year-old pandemic to heel By Ed Silverman STAT+ | Experimental gene therapy for Huntington's markedly slowed disease progression in key trial Results are likely to support the first approval of a genetic treatment for the rare neurodegenerative condition. By Adam Feuerstein STAT+ | Acadia Pharmaceuticals drug for rare genetic condition fails late-stage study The treatment did not curb the devastating symptoms of Prader-Willi syndrome in a clinical trial, according to newly released data. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser